Parilman & Associates Alerts Public to Article Stating that FDA Advisers are Recommending Additional Low T Treatment Studies Due to Potential Heart Risks

Share Article

The testosterone replacement therapy lawyers at Parilman & Associates, whose law firm Web site URL Can be found at, represent consumers across the United States who believe that they have been wrongfully injured by defective products and medications. The attorneys at the firm have been keeping track of the issues regarding testosterone replacement therapy or TRT, and the firm hereby alerts the public to an article that states that FDA advisers have recommended additional studies on these treatments due to the possibility of users facing heart-related health risks.

The low-t lawyers at Parilman & Associates have represented clients across the United States in litigation against drug manufacturers that have allegedly released dangerous or defective medications onto the marketplace. One of the issues that the firm has been handling for clients recently involves those claims that relate to the use of medication taken for low testosterone, or as part of testosterone replacement therapy or TRT. The firm would like to alert the public to a recent article that reveals that advisers with the FDA have recommended additional studies of these medications in order to more clearly assess risks associated with heart problems as a result of their use.

The article was published by Bloomberg News on September 17, 2014, and it was entitled, “Testosterone Drugs May Need Further Study on Heart Risk.” A link to the full article can be found here. The article describes a vote taken by a Food and Drug Administration advisory panel regarding whether or not the manufacturers of these medications should study the potential side effects of testosterone replacement therapy medications. The article further states that the panel voted to recommend additional studies by a count of 20-1.

The same panel again voted 20-1 to revise which patients should be eligible to receive a prescription for these testosterone replacement therapy medications. The article states that the voting panel believes that there is little evidence to suggest that use of these low-T medications is effective for treating dropping levels of testosterone that comes with the natural aging process. It should be noted that the FDA is not required to follow the recommendations of this advisory panel.

According to the article, leading testosterone medications have generated large amounts of revenue for their manufacturers. AbbVie, Inc., the manufacturer of AndroGel, reported sales of more than $1 billion for that drug in 2013. Auxilium Pharmaceuticals Inc. reported sales of more than a quarter-billion dollars for Testim gel and Testopel in 2013.

About Parilman & Associates
Parilman & Associates is a nationwide law firm that represents individuals and classes of consumers who have been injured by defective products. These products include defective consumer products, medical devices and defective medications. The firm also represents clients who have been injured by exposure to asbestos and those who have been wrongfully harmed in different types of accidents. The firm’s Facebook profile can be found at The firm can also be reached by phone at 800-800-DRUG.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Joshua Parilman
Visit website